3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
39
Ovarian Neoplasms
32
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Fallopian Tube Neoplasms
16
Neoplasm Metastasis
14
Pancreatic Neoplasms
9
Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Glioma
6
Stomach Neoplasms
5
Sarcoma
5
Lung Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Metastatic Castration-resistant Prostate Cancer
4
Carcinoma, Ovarian Epithelial
4
Solid Tumors
3
Recurrence
3
Osteosarcoma
3
Neuroendocrine Tumors
3
Lymphoma, Non-Hodgkin
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Interventions
Paclitaxel
8
Hyperthermic Intraperitoneal Chemotherapy
6
Mitomycin
5
Cisplatin
5
Fluorouracil
4
Bevacizumab
4
Oxaliplatin
3
Leucovorin
3
Doxorubicin
3
Cytoreduction Surgical Procedures
3
Carboplatin
3
Blood Specimen Collection
3
sodium thiosulfate
2
pembrolizumab
2
Standard of Care
2
Laparoscopy
2
soluble LAG-3 protein, human
1
relacorilant
1
oregovomab
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
dehydroftorafur
1
avelumab
1
X-Rays
1
Topotecan
1
Taxes
1
Specimen Handling
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
olaparib
×
1 year
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts